Jeffrey G. Lamothe - 17 Jul 2025 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)

Role
EVP, COO
Signature
/s/ SoYoung Kwon, Attorney-In-Fact
Issuer symbol
APVO
Transactions as of
17 Jul 2025
Net transactions value
$0
Form type
4
Filing time
21 Jul 2025, 16:35:23 UTC
Previous filing
04 Mar 2025
Next filing
08 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lamothe Jeffrey G. EVP, COO 2401 4TH AVENUE, SUITE 1050, SEATTLE /s/ SoYoung Kwon, Attorney-In-Fact 21 Jul 2025 0001679967

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APVO Common Stock (post-reverse split May ACTIVE) Options Exercise +5 +500% 6 17 Jul 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APVO Restricted Stock Unit Options Exercise $0 -5 -29% $0.000000 12 17 Jul 2025 Common Stock 17 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2 On July 17, 2024, the reporting person was granted 12,825 (17 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025.